
Repligen (RGEN) Stock Forecast & Price Target
Repligen (RGEN) Analyst Ratings
Bulls say
Repligen's revenue guidance for full-year 2025 has been increased to a range of $715-735 million, reflecting a positive outlook driven by strong performance from contract development and manufacturing organizations (CDMOs) and a 20% growth in biopharma revenue. The consumables segment has outperformed expectations with a growth rate exceeding 20%, while capital equipment sales have also shown high-teens growth. This robust demand across its product categories and geographic markets supports a favorable financial trajectory for the company.
Bears say
Repligen faces significant operational risks, including the potential failure to develop and launch new products, which could hinder its ability to remain competitive in the bioprocessing market. The company's reliance on successful mergers and acquisitions for growth further compounds these challenges, as any inability to finalize such deals could limit expansion opportunities. Additionally, the risks associated with market penetration and competition, coupled with the potential for dilution, contribute to a negative outlook on the stock's future performance.
This aggregate rating is based on analysts' research of Repligen and is not a guaranteed prediction by Public.com or investment advice.
Repligen (RGEN) Analyst Forecast & Price Prediction
Start investing in Repligen (RGEN)
Order type
Buy in
Order amount
Est. shares
0 shares